Prolonged administration of oral phenylbutazone and firocoxib in horses has no impact on selected cytokine and growth factor concentrations in platelet-rich plasma and autologous protein solution
American Journal of Veterinary Research · 2024
DOI: 10.2460/ajvr.24.04.0098 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Veterinary Research, 2024. Verfasst von Kara A Brown und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Studies, University of Pennsylvania School of Veterinary Medicine, New Bolton Center, Kennett Square, PA. Hauptthemen laut MEDLINE: 4-Butyrolactone, Cytokines, Sulfones, Platelet-Rich Plasma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
OBJECTIVE To determine the effects of prolonged administration of the oral NSAIDs phenylbutazone and firocoxib on concentrations of cytokines and growth factors in platelet-rich plasma (PRP) and autologous protein solution (APS). ANIMALS 6 adult University owned horses. METHODS Horses were randomized to receive phenylbutazone (1 g, orally, q 12 h) or firocoxib (57 mg, orally, q 24 h) for 6 days. Blood was obtained and processed for APS (Pro-Stride) and PRP (Restigen) before the administration of NSAIDs and at 7 days (1 day following cessation of NSAIDs). Horses underwent a two-week washout period, during which blood was obtained at 14 days and 21 days. The protocol was repeated with a crossover design. PRP and APS were analyzed for concentrations of platelets, leukocytes, and several cytokines (IL-1β, IL-10, IL-6, IL-8, and tumor necrosis factor-α) and growth factors (PDGF, FGF-2, and TGF-β1) using immunoassays. Plasma was evaluated for drug concentrations. RESULTS No significant differences existed in concentrations of growth factors and cytokines before or after prolonged administration of NSAIDs. There were significant differences in concentrations of leukocytes and platelets in PRP compared to APS, with higher concentrations of leukocytes at the day 7 time point (T) in APS (phenylbutazone) and in concentrations of platelets in APS at T0 (firocoxib) and in APS at T7 (phenylbutazone). CLINICAL RELEVANCE Veterinarians can recommend the administration of these oral NSAIDs prior to obtaining blood for PRP and APS provided a single-day washout period is instituted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Studies, University of Pennsylvania School of Veterinary Medicine, New Bolton Center, Kennett Square, PA.
- University of Pennsylvania School of Veterinary Medicine, Pennsylvania Equine Toxicology and Research Laboratory, West Chester, PA.
ORCID-Profile: Kyla F Ortved
Zitieren
APA
Brown, K. A., Gregorio, E. N., Barot, D., Usimaki, A., Linardi, R. L., Missanelli, J. R., You, Y., Robinson, M. A., & Ortved, K. F. (2024). Prolonged administration of oral phenylbutazone and firocoxib in horses has no impact on selected cytokine and growth factor concentrations in platelet-rich plasma and autologous protein solution. American Journal of Veterinary Research. https://doi.org/10.2460/ajvr.24.04.0098
Vancouver
Brown KA, Gregorio EN, Barot D, Usimaki A, Linardi RL, Missanelli JR, et al. Prolonged administration of oral phenylbutazone and firocoxib in horses has no impact on selected cytokine and growth factor concentrations in platelet-rich plasma and autologous protein solution. American Journal of Veterinary Research. 2024. doi:10.2460/ajvr.24.04.0098
BibTeX
@article{Brown2024,
author = {Brown, Kara A and Gregorio, Elizabeth N and Barot, Dhvani and Usimaki, Alexandra and Linardi, Renata L and Missanelli, Jaclyn R and You, Youwen and Robinson, Mary A and Ortved, Kyla F},
title = {Prolonged administration of oral phenylbutazone and firocoxib in horses has no impact on selected cytokine and growth factor concentrations in platelet-rich plasma and autologous protein solution},
journal = {American Journal of Veterinary Research},
year = {2024},
doi = {10.2460/ajvr.24.04.0098}
}
EUVIMED